MIRA Pharma announces Ketamir-2 publication, Phase 1 progress, SKNY acquisition update

MIRA PHARMACEUTICALS, INC.

Ketamir-2 accepted for publication in Frontiers in Pharmacology; highlights selective NMDA antagonism, no hyperlocomotion, improved oral bioavailability.
Phase 1 trial advancing as planned with dose escalation ongoing; no reported safety concerns.
Phase 2a trial in neuropathic pain expected to initiate by year-end 2025, pending regulatory clearance.
Acquisition of SKNY Pharmaceuticals (including SKNY-1 for obesity/smoking cessation) progressing; SEC filings submitted.

item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.